ActivSignal develops a multiplex paired-antibody amplified detection (MPAD) platform for early cancer detection by profiling proteins and non-DNA biomarkers to create individualized bio-signatures. This technology enables the identification of subtle signatures of early-stage cancer, improving diagnostic accuracy and patient outcomes.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for early cancer detection often lack the sensitivity and specificity needed to identify subtle biomarkers, leading to delayed diagnoses and potentially poorer patient outcomes. Traditional diagnostic approaches may also fail to capture the complex interplay of multiple biomarkers, hindering the creation of individualized risk profiles.
Solution
ActivSignal is developing a multiplex paired-antibody amplified detection (MPAD) platform designed to improve early cancer detection through comprehensive biomarker profiling. The MPAD technology uses carefully selected pairs of antibodies to detect target molecules with high specificity. This approach enables the simultaneous measurement of hundreds of protein and non-DNA biomarkers from a single patient sample, even those present in low abundance. The resulting multi-target bio-signatures are then analyzed using artificial intelligence to identify subtle indicators of early-stage cancer and related conditions, facilitating earlier and more accurate diagnoses.
Target Audience
The primary target audience includes oncologists, diagnostic laboratories, and research institutions focused on improving early cancer detection and personalized medicine.
Features
- Multiplex Paired-Antibody Amplified Detection (MPAD) technology for enhanced specificity in biomarker detection
- Ability to measure hundreds of biomarkers simultaneously from a single, small sample
- High sensitivity for detecting low-abundance proteins and non-DNA biomarkers
- AI-driven analysis of multi-target bio-signatures to identify early cancer indicators
- Creation of individualized bio-signatures for personalized risk assessment